tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Akeso, Inc. Announces Successful Passing of AGM and EGM Resolutions
Company AnnouncementsAkeso, Inc. Announces Successful Passing of AGM and EGM Resolutions
20d ago
9926
Akeso, Inc. Announces Extraordinary General Meeting for Key Resolutions
PremiumCompany Announcements
Akeso, Inc. Announces Extraordinary General Meeting for Key Resolutions
1M ago
9926
Akeso, Inc. Announces Annual General Meeting with Key Resolutions
PremiumCompany Announcements
Akeso, Inc. Announces Annual General Meeting with Key Resolutions
1M ago
9926
Akeso’s Cadonilimab Gains Approval for First-Line Cervical Cancer Treatment
PremiumCompany Announcements
Akeso’s Cadonilimab Gains Approval for First-Line Cervical Cancer Treatment
2M ago
9926
Akeso, Inc. Grants Share Options and RSUs to Boost Employee Motivation
PremiumCompany Announcements
Akeso, Inc. Grants Share Options and RSUs to Boost Employee Motivation
2M ago
9926
Akeso’s Ivonescimab Gains NMPA Approval for NSCLC Treatment
PremiumCompany AnnouncementsAkeso’s Ivonescimab Gains NMPA Approval for NSCLC Treatment
3M ago
9926
FDA Approves Akeso’s Penpulimab for Advanced Nasopharyngeal Carcinoma
Premium
Company Announcements
FDA Approves Akeso’s Penpulimab for Advanced Nasopharyngeal Carcinoma
3M ago
9926
Akeso’s Ivonescimab Shows Promising Results in Lung Cancer Trial
Premium
Company Announcements
Akeso’s Ivonescimab Shows Promising Results in Lung Cancer Trial
3M ago
9926
Akeso’s Ebdarokimab Receives Approval for Psoriasis Treatment in China
PremiumCompany Announcements
Akeso’s Ebdarokimab Receives Approval for Psoriasis Treatment in China
3M ago
9926
Akeso, Inc.: Promising Financial Outlook and Strategic Advancements Drive Buy Rating
PremiumRatings
Akeso, Inc.: Promising Financial Outlook and Strategic Advancements Drive Buy Rating
4M ago
Akeso, Inc. Reports Significant Revenue Decline for 2024
PremiumCompany Announcements
Akeso, Inc. Reports Significant Revenue Decline for 2024
4M ago
9926
Akeso, Inc. Schedules Board Meeting to Approve Annual Results
PremiumCompany Announcements
Akeso, Inc. Schedules Board Meeting to Approve Annual Results
4M ago
9926
Akeso’s Immunotherapy Drugs Join China’s Reimbursement List
PremiumCompany AnnouncementsAkeso’s Immunotherapy Drugs Join China’s Reimbursement List
8M ago
9926
Akeso, Inc. Raises HK$1.924 Billion Through Share Placement
Premium
Company Announcements
Akeso, Inc. Raises HK$1.924 Billion Through Share Placement
9M ago
9926
Akeso, Inc. Aims to Raise HK$1.94 Billion in Share Placement
Premium
Company Announcements
Akeso, Inc. Aims to Raise HK$1.94 Billion in Share Placement
9M ago
9926
Akeso, Inc.’s New Cholesterol Drug Approved in China
PremiumCompany Announcements
Akeso, Inc.’s New Cholesterol Drug Approved in China
10M ago
9926
Akeso’s Breakthrough Drug Wins Approval for Gastric Cancer
PremiumCompany Announcements
Akeso’s Breakthrough Drug Wins Approval for Gastric Cancer
10M ago
9926
Akeso’s Ivonescimab Shows Promise in NSCLC Treatment
PremiumCompany Announcements
Akeso’s Ivonescimab Shows Promise in NSCLC Treatment
10M ago
9926
Akeso, Inc. Reports Mixed Mid-Year Financial Results
PremiumCompany Announcements
Akeso, Inc. Reports Mixed Mid-Year Financial Results
11M ago
9926
Akeso, Inc. Schedules Key Financial Review Meeting
PremiumCompany AnnouncementsAkeso, Inc. Schedules Key Financial Review Meeting
11M ago
9926
Akeso’s Innovative Cancer Drug Advancing Globally
Premium
Company Announcements
Akeso’s Innovative Cancer Drug Advancing Globally
11M ago
9926
Akeso’s Cancer Drug Ivonescimab Shows Promising Trial Results
Premium
Company Announcements
Akeso’s Cancer Drug Ivonescimab Shows Promising Trial Results
12M ago
9926

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >